Analyse TScan Therapeutics, Inc. (TCRX) — Kairos Score 50/100

À propos de TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 0 achats et 0 ventes déclarés par les dirigeants de TScan Therapeutics, Inc..

🏦 Hedge Funds

14 fonds institutionnels déclarent une position sur TCRX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur TCRX.

• TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
• TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.